June 5, 2020

We have recently received many inquiries regarding our Metformin products and the NDMA contamination recently reported by FDA. We note that Ascend was not among the companies requested by FDA to recall Metformin. Ascend markets both Immediate Release and Extended Release Metformin. FDA has not found any issues with regard to manufacturers of Immediate Release Metformin, generally available in 500mg, 850mg, and 1000mg strengths. The recent FDA action solely concerns specific lots of Extended Release Metformin made by five manufacturers not including Ascend.

Manufacturing safe and efficacious products are Ascends top priorities. Ascend presently has no reason to believe there is an NDMA contamination issue with its Metformin products. Our suppliers of active pharmaceutical ingredient (API), who have a long history of providing quality products, have confirmed that there are no issues with regard to NDMA contamination after having conducted comprehensive risk assessment of their manufacturing process, starting materials and final API, and testing of the API. In an abundance of caution and in accordance with FDA guidelines and regulations, Ascend is undertaking additional testing to confirm there is no NDMA contamination in its Metformin products. Ascend has a long history of providing quality products to the public. If an issue were to present regarding NDMA contamination in Ascends Metformin products, we would immediately take appropriate action in accordance with FDA guidelines and regulations. Ascends obligation to the community-at-large to supply safe and efficacious products is paramount and we will continue to comply with all FDA directives, regulations and guidelines.